Lee Taehyoung, Guo Yanbo, Vij Saahil, Bansal Rahul, Wong Nathan C, Shayegan Bobby
Department of Surgery, Division of Urology, McMaster University, Hamilton ON, Canada.
Can Urol Assoc J. 2017 Jul;11(7):E315-E317. doi: 10.5489/cuaj.4324. Epub 2017 Jul 11.
Prostate cancer remains the most frequently diagnosed cancer among men. The combination of clinical stage, serum prostate-specific antigen (PSA), and Gleason score (biopsy) assists in predictive assessment of pathological stage and prognosis. Furthermore, pathological criteria, including Gleason score, surgical margin status, extracapsular extension, seminal vesicle invasion, and lymph node involvement, provide prognostication in patients undergoing radical prostatectomy (RP). In this paper, we present a case of a patient with high-risk prostate cancer with persistent PSA elevation post-RP who experiences a complete regression of PSA without any adjuvant therapy. To the authors' knowledge, such a finding has not been described in the literature previously.
前列腺癌仍然是男性中最常被诊断出的癌症。临床分期、血清前列腺特异性抗原（PSA）和 Gleason 评分（活检）相结合有助于对病理分期和预后进行预测评估。此外，包括 Gleason 评分、手术切缘状态、包膜外侵犯、精囊侵犯和淋巴结受累在内的病理标准，可为接受根治性前列腺切除术（RP）的患者提供预后评估。在本文中，我们报告了一例高危前列腺癌患者，该患者在 RP 后 PSA 持续升高，但未接受任何辅助治疗，PSA 却完全消退。据作者所知，此前文献中尚未描述过此类发现。
